Fresenius Se ( (FSNUY) ) has released its Q3 earnings. Here is a breakdown of the information Fresenius Se presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fresenius SE & Co. KGaA is a global healthcare company based in Germany, specializing in biopharmaceuticals, clinical nutrition, medical technology, and hospital management, with significant operations in Germany and Spain.
In its Q3 2025 earnings report, Fresenius demonstrated strong financial performance, highlighted by a 6% organic revenue growth and a 14% increase in core earnings per share. The company has raised its full-year EBIT growth guidance, reflecting its robust operational execution.
Key financial metrics include a group revenue of €5,477 million and an EBIT of €574 million, both showing significant growth. Fresenius Kabi and Fresenius Helios were major contributors, with Fresenius Kabi achieving a 7% organic revenue growth and Fresenius Helios showing a 5% increase. The company’s net debt/EBITDA ratio remains stable at 3.0x, supported by strong cash flow.
Looking ahead, Fresenius is optimistic about its growth trajectory, with plans to invest in digital health and advanced therapies. The company aims to continue its disciplined execution and performance-oriented culture to drive sustainable value for its stakeholders.